Rates and Patterns of Recurrence after Curative Intent Resection for Gastric Cancer: A United States Multi-Institutional Analysis

Spolverato, Gaya; Ejaz, Aslam; Kim, Yuhree; Squires, Malcolm H.; Poultsides, George A.; Fields, Ryan C.; Schmidt, Carl; Weber, Sharon M.; Votanopoulos, Konstantinos I.; Maithel, Shishir K.; Pawlik, Timothy M.

doi:10.1016/j.jamcollsurg.2014.03.062

Cited by 150 publications

(135 citation statements)

References 32 publications

Supporting

Mentioning

116

Contrasting

Unclassified

Order By: Relevance

“…However, the rate of recurrence reaches up to 60% (5,6). For these patients, the use of neoadjuvant (7) or adjuvant treatment with chemotherapy (8,9), radiotherapy (10) or both (11) has shown to improve OS and disease-free survival (DFS) in several randomized clinical trials.…”

mentioning

confidence: 99%

Predictors of overall survival after surgery in gastric cancer patients from a Latin-American country

Cordero-García¹,

Ramos-Esquivel²,

Alpízar‐Alpízar³

2018

J. Gastrointest. Oncol.

View full text Add to dashboard Cite

mentioning

confidence: 99%

Predictors of overall survival after surgery in gastric cancer patients from a Latin-American country

Cordero-García¹,

Ramos-Esquivel²,

Alpízar‐Alpízar³

2018

J. Gastrointest. Oncol.

View full text Add to dashboard Cite

“…PC accounts for 35% of synchronous metastasis and is the sole site of metastasis in 9% of cases [3]. In the recurrent setting, peritoneal carcinomatosis can occur in up to 46% of cases and as the only site in up to 40% of cases [3,[43][44][45][46][47][48].…”

Section: Discussionmentioning

confidence: 99%

Survival outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from gastric cancer: a systematic review

Chia

Seshadri

Képénékian³

et al. 2016

Pleura and Peritoneum

View full text Add to dashboard Cite

Background: The current treatment of choice for peritoneal carcinomatosis from gastric cancer is systemic chemotherapy. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is a new aggressive form of loco-regional treatment that is currently being used in pseudomyxoma peritoneii, peritoneal mesothelioma and peritoneal carcinomatosis from colorectal cancer. It is still under investigation for its use in gastric cancer. Methods: The literature between 1970 and 2016 was surveyed systematically through a review of published studies on the treatment outcomes of CRS and HIPEC for peritoneal carcinomatosis from gastric cancer. Results: Seventeen studies were included in this review. The median survival for all patients ranged from 6.6 to 15.8 months. The 5-years overall survival ranged from 6 to 31%. For patients with complete cytoreduction, the median survival was 11.2 to 43.4 months and the 5-years overall survival was 13 % to 23%. Important prognostic factors were found to be a low peritoneal carcarcinomatosis index (PCI) score and the completeness of cytoreduction.

show abstract

“…More recently, the commonest site of recurrence among 817 patients identified in the US Gastric Cancer Collaborative database to have undergone curative intent resection was reported to be peritoneal (n = 92), with peritoneal-only metastasis found in 47 patients (19.3 %) [23]. Thus prevention of peritoneal metastasis is an important issue after the surgical treatment for gastric cancer worldwide.…”

Section: Discussionmentioning

confidence: 99%

Feasibility of weekly intraperitoneal versus intravenous paclitaxel therapy delivered from the day of radical surgery for gastric cancer: a preliminary safety analysis of the INPACT study, a randomized controlled trial

et al. 2016

View full text Add to dashboard Cite

Background Peritoneal carcinomatosis is common after curative resection of gastric cancer. Intraperitoneal administration of paclitaxel (PTX) is known to control ovarian peritoneal metastases. Patients and methods Patients with either linitis plastica or T4 cancer with high risk of peritoneal metastasis or recurrence but whose cancer was considered resectable were preregistered. After their cancer had been confirmed intraoperatively as resectable, the patients were randomized into either group A (PTX at 60 mg/m 2 intraperitoneally on the day of surgery and on days 14, 21, 28, 42, 49, and 56) or group B (PTX at 80 mg/m 2 administered intravenously by the identical schedule) before being treated by evidence-based chemotherapy. The primary end point was the 2-year survival rate. Safety, the secondary end point, was also analyzed. The study has been registered as UMIN000002957. Results Of 177 preregistered patients, 83 underwent treatment (39 by intraperitoneal administration and 44 by intravenous administration). There was no difference in patient demographics between the two groups. The incidences of surgical complications were similar between the groups, except for transient bowel obstruction observed exclusively in group A. The relative dose intensity of PTX was 81.4 % for group A and 76.3 % for group B. There was one death due to pulmonary thrombosis and a case of anaphylaxis that led to termination of the protocol treatment (group B). Other adverse events were mild and manageable. Conclusions Intraperitoneal administration of PTX from the day of gastrectomy did not result in a higher incidence of surgical complications and adverse reactions when compared with intravenous administration of PTX.

show abstract

Rates and Patterns of Recurrence after Curative Intent Resection for Gastric Cancer: A United States Multi-Institutional Analysis

Cited by 150 publications

References 32 publications

Predictors of overall survival after surgery in gastric cancer patients from a Latin-American country

Predictors of overall survival after surgery in gastric cancer patients from a Latin-American country

Survival outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from gastric cancer: a systematic review

Feasibility of weekly intraperitoneal versus intravenous paclitaxel therapy delivered from the day of radical surgery for gastric cancer: a preliminary safety analysis of the INPACT study, a randomized controlled trial

Contact Info

Product

Resources

About